Thrombocytopenia Clinical Trials

• Men and women, 18-75 years of age;

• Histopathological or cytological examination confirmed cancer , chemotherapy cycle of 21 days;

• Participant experienced thrombocytopenia and chemotherapy delay;

• ECOG performance status 0-1;

• The estimated survival time at screening is ≥12 weeks, and the current chemotherapy regimen can be accepted for at least 2 cycles.